# A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

> **NCT03666728** · PHASE2 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** BP102

## Key facts

- **NCT ID:** NCT03666728
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-30
- **Primary completion:** 2020-03-11
- **Final completion:** 2020-03-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** changes in the R\&D strategy
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666728, "A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03666728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*